Patents by Inventor Mei You

Mei You has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion protein and nucleic acid encoding sequence thereof, and uses of the same
    Patent number: 12221483
    Abstract: The present disclosure provides a fusion protein and the nucleic acid encoding sequence thereof, and uses of the same. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.
    Type: Grant
    Filed: January 30, 2024
    Date of Patent: February 11, 2025
    Assignee: CHINA MEDICAL UNIVERSITY HOSPITAL
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Shi-Wei Huang, Chih-Ming Pan, Mei-Chih Chen, Yu-Chuan Lin, Yeh Chen, Yi-Wen Chen, Ming-You Shie, Kai-Wen Kan
  • Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]
    Patent number: 12215113
    Abstract: Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
    Type: Grant
    Filed: January 30, 2024
    Date of Patent: February 4, 2025
    Assignee: Biomea Fusion, Inc.
    Inventors: Satish Goud Puppali, James T. Palmer, Thorsten A. Kirschberg, Angelina Sau Man Wong, Heow Meng Tan, Jay Li, Jing Lin, Ming Gao, Junlu Ding, Shuang Li, Yuyao Gu, Hongyan He, Bo Zheng, Yanjing Zhou, Mei You
  • CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE AS IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20240417404
    Abstract: Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
    Type: Application
    Filed: August 20, 2024
    Publication date: December 19, 2024
    Inventors: Satish Goud Puppali, James T. Palmer, Thorsten A. Kirschberg, Angelina Sau Man Wong, Heow Meng Tan, Jay Li, Jing Lin, Ming Gao, Junlu Ding, Shuang Li, Yuyao GU, Hongyan He, Bo Zheng, Yanjing Zhou, Mei You, Yihong Qiu
  • CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL][PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL[METHYL]-2-PYRIDINECARBOXAMIDE AS A COVALENT INHIBITOR OF MENIN-MLL INTERACTION
    Publication number: 20240300950
    Abstract: Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 30, 2024
    Publication date: September 12, 2024
    Inventors: Satish Goud Puppali, James T. Palmer, Thorsten A. Kirschberg, Angelina Sau Man Wong, Heow Meng Tan, Jay Li, Ming Lin, Ming Gao, Junlu Ding, Shuang Li, Yuyao GU, Hongyan He, Bo Zheng, Yanjing Zhou, Mei You, Yihong Qiu